{"id":"https://openalex.org/W2107680428","doi":"https://doi.org/10.3111/13696998.2010.529377","title":"A comparison of preferences for two GLP-1 products \u2013 liraglutide and exenatide \u2013 for the treatment of type 2 diabetes","display_name":"A comparison of preferences for two GLP-1 products \u2013 liraglutide and exenatide \u2013 for the treatment of type 2 diabetes","publication_year":2010,"publication_date":"2010-11-01","ids":{"openalex":"https://openalex.org/W2107680428","doi":"https://doi.org/10.3111/13696998.2010.529377","mag":"2107680428","pmid":"https://pubmed.ncbi.nlm.nih.gov/21034377"},"language":"en","primary_location":{"id":"doi:10.3111/13696998.2010.529377","doi":"https://doi.org/10.3111/13696998.2010.529377","is_oa":true,"landing_page_url":"https://doi.org/10.3111/13696998.2010.529377","pdf_url":"https://www.tandfonline.com/doi/pdf/10.3111/13696998.2010.529377?needAccess=true","source":{"id":"https://openalex.org/S155267287","display_name":"Journal of Medical Economics","issn_l":"1369-6998","issn":["1369-6998","1941-837X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["abdc-c","anvur-scientific","cwts-core","dongbi-d","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320449","host_organization_name":"Informa","host_organization_lineage":["https://openalex.org/P4310320449"],"host_organization_lineage_names":["Informa"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Medical Economics","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"bronze","oa_url":"https://www.tandfonline.com/doi/pdf/10.3111/13696998.2010.529377?needAccess=true","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5017303016","display_name":"Michael R. Polster","orcid":"https://orcid.org/0000-0002-2025-7140","observed_orcids":["https://orcid.org/0000-0002-2025-7140"]},"institutions":[],"countries":[],"is_corresponding":true,"raw_author_name":"Michael Polster","raw_affiliation_strings":["National Analysts Worldwide, Philadelphia, PA 19103, USA. mpolster@nationalanalysts.com","National Analysts Worldwide, Philadelphia, PA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"National Analysts Worldwide, Philadelphia, PA 19103, USA. mpolster@nationalanalysts.com","institution_ids":[]},{"raw_affiliation_string":"National Analysts Worldwide, Philadelphia, PA, USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5075598801","display_name":"Elaine L. Zanutto","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Elaine Zanutto","raw_affiliation_strings":["National Analysts Worldwide, Philadelphia, PA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"National Analysts Worldwide, Philadelphia, PA, USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5089629082","display_name":"Susan McDonald","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Susan McDonald","raw_affiliation_strings":["National Analysts Worldwide, Philadelphia, PA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"National Analysts Worldwide, Philadelphia, PA, USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":null,"display_name":"Christopher Conner","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Christopher Conner","raw_affiliation_strings":["Novo Nordisk Inc., Princeton, NJ, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Novo Nordisk Inc., Princeton, NJ, USA","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5109998971","display_name":"Mette Hammer","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I189090001","display_name":"Novo Nordisk (Denmark)","ror":"https://ror.org/0435rc536","country_code":"DK","type":"company","lineage":["https://openalex.org/I189090001","https://openalex.org/I2801134892","https://openalex.org/I4210159963"]}],"countries":["DK"],"is_corresponding":false,"raw_author_name":"Mette Hammer","raw_affiliation_strings":["Novo Nordisk A/S, Bagsv\u00e6rd, Denmark"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Novo Nordisk A/S, Bagsv\u00e6rd, Denmark","institution_ids":["https://openalex.org/I189090001"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":["https://openalex.org/A5017303016"],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":7.5732,"has_fulltext":true,"cited_by_count":60,"citation_normalized_percentile":{"value":0.96728031,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":88,"max":99},"biblio":{"volume":"13","issue":"4","first_page":"655","last_page":"661"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10804","display_name":"Health Systems, Economic Evaluations, Quality of Life","score":0.5601000189781189,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},"topics":[{"id":"https://openalex.org/T10804","display_name":"Health Systems, Economic Evaluations, Quality of Life","score":0.5601000189781189,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},{"id":"https://openalex.org/T10401","display_name":"Diabetes Treatment and Management","score":0.4032999873161316,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10841","display_name":"Economic and Environmental Valuation","score":0.024800000712275505,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/liraglutide","display_name":"liraglutide","score":0.9520000219345093},{"id":"https://openalex.org/keywords/exenatide","display_name":"exenatide","score":1.0},{"id":"https://openalex.org/keywords/type-2-diabetes","display_name":"type 2 diabetes","score":0.9089999794960022},{"id":"https://openalex.org/keywords/patient-preferences","display_name":"patient preferences","score":0.7630000114440918},{"id":"https://openalex.org/keywords/glp-1-receptor-agonists","display_name":"GLP-1 receptor agonists","score":0.9359999895095825},{"id":"https://openalex.org/keywords/time-trade-off","display_name":"time trade-off","score":0.9160000085830688},{"id":"https://openalex.org/keywords/conjoint-analysis","display_name":"conjoint analysis","score":0.8370000123977661},{"id":"https://openalex.org/keywords/health-utility","display_name":"health utility","score":0.7400000095367432},{"id":"https://openalex.org/keywords/hba1c","display_name":"HbA1c","score":0.8180000185966492},{"id":"https://openalex.org/keywords/nausea","display_name":"nausea","score":0.9729999899864197},{"id":"https://openalex.org/keywords/hypoglycemia","display_name":"hypoglycemia","score":0.9990000128746033},{"id":"https://openalex.org/keywords/dosing-frequency","display_name":"dosing frequency","score":0.9369999766349792},{"id":"https://openalex.org/keywords/medication-preferences","display_name":"drug preference","score":0.3619999885559082}],"concepts":[{"id":"https://openalex.org/C2780533449","wikidata":"https://www.wikidata.org/wiki/Q417762","display_name":"Exenatide","level":4,"score":0.913615345954895},{"id":"https://openalex.org/C2781308992","wikidata":"https://www.wikidata.org/wiki/Q2526479","display_name":"Liraglutide","level":4,"score":0.8909144997596741},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7973542213439941},{"id":"https://openalex.org/C2780580376","wikidata":"https://www.wikidata.org/wiki/Q186889","display_name":"Nausea","level":2,"score":0.7032667398452759},{"id":"https://openalex.org/C2780668416","wikidata":"https://www.wikidata.org/wiki/Q202758","display_name":"Hypoglycemia","level":3,"score":0.6415087580680847},{"id":"https://openalex.org/C2777288759","wikidata":"https://www.wikidata.org/wiki/Q4164182","display_name":"Dosing","level":2,"score":0.6100796461105347},{"id":"https://openalex.org/C2777180221","wikidata":"https://www.wikidata.org/wiki/Q3025883","display_name":"Type 2 diabetes","level":3,"score":0.5089461803436279},{"id":"https://openalex.org/C2778054375","wikidata":"https://www.wikidata.org/wiki/Q203973","display_name":"Conjoint analysis","level":3,"score":0.4294854402542114},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.37840592861175537},{"id":"https://openalex.org/C555293320","wikidata":"https://www.wikidata.org/wiki/Q12206","display_name":"Diabetes mellitus","level":2,"score":0.3332921266555786},{"id":"https://openalex.org/C2781249084","wikidata":"https://www.wikidata.org/wiki/Q908656","display_name":"Preference","level":2,"score":0.18227097392082214},{"id":"https://openalex.org/C134018914","wikidata":"https://www.wikidata.org/wiki/Q162606","display_name":"Endocrinology","level":1,"score":0.17188358306884766},{"id":"https://openalex.org/C2779306644","wikidata":"https://www.wikidata.org/wiki/Q2002370","display_name":"Insulin","level":2,"score":0.1608123779296875},{"id":"https://openalex.org/C33923547","wikidata":"https://www.wikidata.org/wiki/Q395","display_name":"Mathematics","level":0,"score":0.07529118657112122},{"id":"https://openalex.org/C105795698","wikidata":"https://www.wikidata.org/wiki/Q12483","display_name":"Statistics","level":1,"score":0.06588783860206604}],"mesh":[{"descriptor_ui":"D000069450","descriptor_name":"Liraglutide","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000077270","descriptor_name":"Exenatide","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D003924","descriptor_name":"Diabetes Mellitus, Type 2","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D004334","descriptor_name":"Drug Administration Schedule","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006442","descriptor_name":"Glycated Hemoglobin","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007003","descriptor_name":"Hypoglycemia","qualifier_ui":"Q000139","qualifier_name":"chemically induced","is_major_topic":false},{"descriptor_ui":"D007004","descriptor_name":"Hypoglycemic Agents","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D007004","descriptor_name":"Hypoglycemic Agents","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D007004","descriptor_name":"Hypoglycemic Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009325","descriptor_name":"Nausea","qualifier_ui":"Q000139","qualifier_name":"chemically induced","is_major_topic":false},{"descriptor_ui":"D010455","descriptor_name":"Peptides","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D010455","descriptor_name":"Peptides","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D010455","descriptor_name":"Peptides","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D011788","descriptor_name":"Quality of Life","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D012959","descriptor_name":"Socioeconomic Factors","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D014688","descriptor_name":"Venoms","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D014688","descriptor_name":"Venoms","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D014688","descriptor_name":"Venoms","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D052216","descriptor_name":"Glucagon-Like Peptide 1","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D052216","descriptor_name":"Glucagon-Like Peptide 1","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D052216","descriptor_name":"Glucagon-Like Peptide 1","qualifier_ui":"Q000031","qualifier_name":"analogs & derivatives","is_major_topic":true},{"descriptor_ui":"D052216","descriptor_name":"Glucagon-Like Peptide 1","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D057240","descriptor_name":"Patient Preference","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true}],"locations_count":2,"locations":[{"id":"doi:10.3111/13696998.2010.529377","doi":"https://doi.org/10.3111/13696998.2010.529377","is_oa":true,"landing_page_url":"https://doi.org/10.3111/13696998.2010.529377","pdf_url":"https://www.tandfonline.com/doi/pdf/10.3111/13696998.2010.529377?needAccess=true","source":{"id":"https://openalex.org/S155267287","display_name":"Journal of Medical Economics","issn_l":"1369-6998","issn":["1369-6998","1941-837X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["abdc-c","anvur-scientific","cwts-core","dongbi-d","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320449","host_organization_name":"Informa","host_organization_lineage":["https://openalex.org/P4310320449"],"host_organization_lineage_names":["Informa"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Medical Economics","raw_type":"journal-article"},{"id":"pmid:21034377","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/21034377","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of medical economics","raw_type":"Journal Article"}],"best_oa_location":{"id":"doi:10.3111/13696998.2010.529377","doi":"https://doi.org/10.3111/13696998.2010.529377","is_oa":true,"landing_page_url":"https://doi.org/10.3111/13696998.2010.529377","pdf_url":"https://www.tandfonline.com/doi/pdf/10.3111/13696998.2010.529377?needAccess=true","source":{"id":"https://openalex.org/S155267287","display_name":"Journal of Medical Economics","issn_l":"1369-6998","issn":["1369-6998","1941-837X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["abdc-c","anvur-scientific","cwts-core","dongbi-d","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320449","host_organization_name":"Informa","host_organization_lineage":["https://openalex.org/P4310320449"],"host_organization_lineage_names":["Informa"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Medical Economics","raw_type":"journal-article"},"sustainable_development_goals":[{"score":0.9940000176429749,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[{"id":"https://openalex.org/study-designs/observational-study","display_name":"Observational Study"}],"awards":[],"funders":[{"id":"https://openalex.org/F4320322436","display_name":"Novo Nordisk","ror":"https://ror.org/0435rc536"}],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W2107680428.pdf","grobid_xml":"https://content.openalex.org/works/W2107680428.grobid-xml"},"referenced_works_count":31,"referenced_works":["https://openalex.org/W123908341","https://openalex.org/W1537598136","https://openalex.org/W1541705153","https://openalex.org/W1782204000","https://openalex.org/W1968744224","https://openalex.org/W1974956372","https://openalex.org/W1980534942","https://openalex.org/W2010314406","https://openalex.org/W2016362182","https://openalex.org/W2043951092","https://openalex.org/W2046553857","https://openalex.org/W2046645679","https://openalex.org/W2047375989","https://openalex.org/W2066861619","https://openalex.org/W2067626357","https://openalex.org/W2087596550","https://openalex.org/W2099332381","https://openalex.org/W2101684363","https://openalex.org/W2108525470","https://openalex.org/W2133469585","https://openalex.org/W2134605330","https://openalex.org/W2144835455","https://openalex.org/W2146901298","https://openalex.org/W2153836018","https://openalex.org/W2157146861","https://openalex.org/W2170606300","https://openalex.org/W2433106377","https://openalex.org/W2502806512","https://openalex.org/W3011865677","https://openalex.org/W3124354616","https://openalex.org/W4236501586"],"related_works":["https://openalex.org/W2096416969","https://openalex.org/W2938716486","https://openalex.org/W2478113780","https://openalex.org/W2585146202","https://openalex.org/W2590405401","https://openalex.org/W2543582919","https://openalex.org/W2920836114","https://openalex.org/W4313416712","https://openalex.org/W4353074429","https://openalex.org/W2922465073"],"abstract_inverted_index":{"OBJECTIVE:":[0],"To":[1],"use":[2],"time":[3,93],"trade-off":[4,94],"(TTO)":[5],"to":[6,61,73],"compare":[7],"patient":[8],"preferences":[9],"for":[10,18,115],"profiles":[11,190],"of":[12,21,42,45,58,66,80,83,92,106,128],"two":[13],"glucagon-like":[14],"peptide":[15],"(GLP-1)":[16],"products":[17],"the":[19,56,97,139,154,165,202],"treatment":[20],"type":[22,183],"2":[23,184],"diabetes":[24,185],"(liraglutide":[25],"and":[26,47,54,89,110,130,173,187,217,224],"exenatide)":[27],"that":[28,158],"vary":[29],"on":[30,201,214],"four":[31,203],"key":[32],"attributes":[33,60,204],"-":[34,53],"efficacy":[35,159,216],"(as":[36],"measured":[37,160],"by":[38,126,161,170],"hemoglobin":[39,162],"A(1C)),":[40],"incidence":[41,44],"nausea,":[43,171],"hypoglycemia,":[46,172],"dosing":[48,174],"frequency":[49],"(QD":[50],"vs.":[51,145],"BID)":[52],"measure":[55],"contribution":[57],"those":[59],"preferences.":[62],"METHODS:":[63],"A":[64],"total":[65],"382":[67],"people":[68],"with":[69,103],"T2DM":[70],"were":[71,101],"recruited":[72],"participate":[74],"in":[75,132],"an":[76],"internet-based":[77],"survey":[78],"consisting":[79],"a":[81,86,90,112],"series":[82],"health-related":[84],"questions,":[85],"conjoint":[87,98,155],"exercise":[88,114],"set":[91],"items.":[95],"In":[96],"exercise,":[99],"respondents":[100,129],"presented":[102],"eight":[104],"pairs":[105],"hypothetical":[107],"GLP-1":[108],"profiles,":[109],"completed":[111],"time-tradeoff":[113],"each":[116],"pair.":[117],"RESULTS:":[118],"The":[119],"product":[120,140,189],"profile":[121,141],"representing":[122,142],"liraglutide":[123,208],"was":[124],"preferred":[125],"96%":[127],"resulted":[131],"significantly":[133],"higher":[134],"health":[135],"utilities":[136],"(0.038)":[137],"than":[138,221],"exenatide":[143],"(0.978":[144],"0.94,":[146],"p":[147],"<":[148],"0.05).":[149],"Estimated":[150],"preference":[151],"scores":[152],"from":[153,193],"analysis":[156],"revealed":[157],"A(1C)":[163],"is":[164,212],"most":[166],"important":[167],"attribute,":[168],"followed":[169],"schedule.":[175],"LIMITATIONS:":[176],"On-line":[177],"participants":[178],"may":[179],"not":[180,196],"represent":[181],"'typical'":[182],"patients,":[186],"brief":[188],"represented":[191],"results":[192],"clinical":[194,197],"trials,":[195],"practice":[198],"CONCLUSION:":[199],"Based":[200],"presented,":[205],"patients":[206],"prefer":[207],"over":[209],"exenatide.":[210],"Preference":[211],"based":[213],"superior":[215],"less":[218,222],"nausea":[219],"more":[220],"hypoglycemia":[223],"once-daily":[225],"dosing.":[226]},"counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2025,"cited_by_count":1},{"year":2024,"cited_by_count":1},{"year":2023,"cited_by_count":3},{"year":2022,"cited_by_count":6},{"year":2021,"cited_by_count":5},{"year":2020,"cited_by_count":1},{"year":2019,"cited_by_count":7},{"year":2018,"cited_by_count":7},{"year":2017,"cited_by_count":3},{"year":2016,"cited_by_count":4},{"year":2015,"cited_by_count":6},{"year":2014,"cited_by_count":4},{"year":2013,"cited_by_count":6},{"year":2012,"cited_by_count":2}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2016-06-24T00:00:00"}